ArticleBMC ophthalmology2025
XEN‑45 implantation for refractory secondary glaucoma.
Article in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Preserflo MicroShunt Outcomes in Rare and Refractory Glaucoma Entities Compared with Matched Primary Open-Angle Glaucoma Controls: A Retrospective Exploratory Study.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundTo evaluate the efficacy and safety of XEN-45 gel stent in different types of refractory secondary glaucoma (SG).
methodsThis retrospective analysis included 39 patients (42 eyes) who underwent XEN-45 gel stent implantation for medically uncontrolled SG using two approaches, ab externo closed-conjunctiva (AEC) and ab externo open-conjunctiva (AEO). The intraocular pressure (IOP) and numbers of antiglaucoma medications were compared between preoperative and postoperative values. The requirement for revision, bleb needling and further glaucoma surgery were recorded.
resultsIOP was decreased significantly from 31.79 ± 10.62 mmHg to 14.06 ± 4.45 mmHg (p < 0.001) by the final visit (averaging 13.74 ± 7.96 months post-surgery) and the number of antiglaucoma medications was reduced from 3.67 ± 0.87 to 0.36 ± 0.82 (p < 0.001). Twenty-three eyes (54.8%) required postoperative needling. Twelve eyes (28.6%) required open conjunctival bleb revision. At the final follow-up, 33 eyes (78.6%) achieved complete success, defined as an IOP of 18 mmHg or lower without medications, and 36 eyes (85.7%) reached qualified success, maintaining an IOP of 18 mmHg or lower with medications, while 2 eyes (4.76%) needed trabeculectomy. There were no vision-threatening and ocular infection complications intraoperatively or postoperatively.
conclusionsXEN-45 gel stent provides a minimally invasive option for eyes with SG and requires close monitoring and timely postoperative management. The incidence of adverse events following the procedure is rare.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.